Cologne, September 7, 2015 – New Oncology today announced that an abstract highlighting the company's progress in clinical cancer genome diagnostics will be presented at the 16th World Conference on Lung Cancer taking place September 6 – 9, 2015, in Denver, USA.
Date & Time: Wednesday, September 9th, 2015, 9.45am - 10.45am and 3.45pm - 4.45pm
Title: Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics
Abstract: # 2748
Presenter: Dr. Rafal Dziadziuszko
"We analyzed primary tumor samples for our network of clinical partners using our NEO platform to detect therapeutically relevant gene fusions," commented Dr. Lukas C. Heukamp, Medical Director of New Oncology. "In the cohort published today, our findings showed discrepant results in all cases when compared with fluorescent in situ hybridization (FISH), the current gold standard of gene fusion diagnostics. Clinical response data were available for all patients, and tumor sensitivity was always in line with the results obtained by NEO. With gene fusions becoming more and more important as cancer drug targets, the need for reliable results will drastically increase. With our NEO technology, we are perfectly adapted to analyze tumor samples that do not match the quality requirements for FISH analysis or for which only limited material is available.”
About New Oncology
New Oncology’s proprietary pan-cancer diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. NEO reliably detects actionable genetic alterations with short turn-around times in routine clinical specimens such as paraffin embedded tissue, cytology or blood. In contrast to conventional testing, NEO identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample. New Oncology works with a tumor board of renowned cancer experts, facilita-ting translation of the latest targeted therapy findings into optimized patient care.
Dr. Jutta Fritz
NEO New Oncology AG